Recent studies have raised concerns that the diabetes drug Tradjenta could over-stimulate the pancreas and cause pancreatitis, a risk-factor for pancreatic cancer. It is also linked to rhabdomyolysis.
What You Can Do & How We Can Help
The Schmidt Firm, PLLC is currently accepting Tradjenta induced injury cases in all 50 states. If you or somebody you know has been diagnosed with pancreatic cancer, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Drug Litigation Group or call toll free 24 hours a day at (866) 920-0753.
FDA Evaluating Rhabdomyolysis Risk
The FDA is evaluating a potential signals of a serious risk and new safety information linking DPP4 diabetes drugs and rhabdomyolysis. This potentially life-threatening kidney side effect was identified by the FDA Adverse Event Reporting System (FAERS) between April and June 2017.
Tradjenta and Pancreatic Cancer
Tradjenta (linagliptin) helps adults with type-2 diabetes control their blood-sugar levels. It belongs to a class of drugs called incretin mimetics, which work by stimulating the pancreas to make more insulin.
Type-2 diabetes is a risk-factor for pancreatitis (pancreatic inflammation) and pancreatic cancer. Because Tradjenta relies so heavily on the pancreas, experts are concerned that it could over-stimulate the pancreas and increase the risk of inflammation.
Over time, chronic inflammation in the pancreas increases the risk of DNA mutations that cause cancer. The FDA has been monitoring pancreatic side effects from incretin mimetics for many years. The first warning was issued in 2008. In 2009, the agency asked drug-makers to study the risk of pancreatic cancer.
In 2010, a study published in Gastroenterology linked the two most popular incretin mimetic diabetes drugs with higher rates of pancreatitis and pancreatic cancer. In 2013, a study published in Diabetes reported that pre-cancerous growths called pancreatic duct metaplasia were discovered in several pancreases from people who used incretin mimetics.
In response to these studies, the FDA issued a Safety Communication and opened and investigation in March 2013. However, the agency did not update the Warnings & Precautions for Tradjenta or other incretin mimetic drugs.
Judges Consolidate Hundreds of Lawsuits in MDL
Over 750 lawsuits involving pancreatic side effects of diabetes drugs have been centralized in a federal Multi-District Litigation (MDL No. 2452) in California. Unlike a class action, all of the lawsuits are individual and each case can have its own outcome. Like a class action, the MDL or “mass-tort” improves efficiency, eliminates duplicative discovery, and avoids conflicting rulings in different courts.
What is the problem?
The Schmidt Firm, PLLC is nationally recognized as a class action law firm. However, our attorneys are not filing a Tradjenta class action. Instead, we are filing individual lawsuits. If you were diagnosed with pancreatic cancer, you could receive compensation.
About Class Actions
Class actions are a convenient way to help a lot of people resolve their legal claims all at once. Instead of everyone filing a lawsuit alone, everyone joins together and shares any payout awarded by a jury verdict or settlement.
Why Our Law Firm is Filing Individual Lawsuits as Opposed to a Class Action
Members of class actions may have to accept a “low-ball” settlement or watch attorneys take a huge cut of the payout. In some cases, this does not leave much remaining to share among everyone in the lawsuit.
Because class actions are not designed to maximize compensation for individual plaintiffs, our attorneys are filing individual lawsuits. We specialize in holding pharmaceutical companies accountable for failing to warn about severe side effects from dangerous medications.
Do I have a Tradjenta Lawsuit?
The Schmidt Firm, PLLC is currently accepting Tradjenta induced injury cases in all 50 states. If you or somebody you know has been diagnosed with pancreatic cancer, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Drug Litigation Group or call toll free 24 hours a day at (866) 920-0753.
Attention Lawyers: We consider a referral from another law firm to be one of the greatest compliments. If your firm is interested in referring us a case or for us to send you a list of previous award judgments and/or average referral fees, please visit the Lawyer Referral section of our website.
The Schmidt Firm, PLLC has been recognized as one of the nation’s leading plaintiffs' law firms and handles cases in all 50 states. We are very proud of our legal achievements, but equally self-respecting of our firm's reputation for providing personal attention to each and every client we represent.
